Clinical Trial Update: A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas [Phase 1]

View source ↗

Summary

A Phase 1 study of ATG-101 in patients with metastatic/advanced solid tumors and mature B-cell non-Hodgkin lymphoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Solid Tumors

Drugs mentioned

• ATG-101

Snippet

Sponsor: Antengene Biologics Limited | Conditions: Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Status: TERMINATED